Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.05 CHF | +0.20% | +0.12% | +4.93% |
05:51pm | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
05:01pm | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.93% | 199B | |
+33.95% | 664B | |
+29.29% | 567B | |
-7.13% | 354B | |
+19.22% | 330B | |
+4.72% | 286B | |
+13.79% | 234B | |
-9.78% | 196B | |
-4.52% | 148B | |
-10.72% | 145B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis Says Initial Data from Phase 3 Trial Show No Difference Between Crizanlizumab, Placebo